KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Other Non-Current Assets (2016 - 2026)

Gsk has reported Other Non-Current Assets over the past 18 years, most recently at $3.2 billion for Q1 2026.

  • For Q1 2026, Other Non-Current Assets rose 24.92% year-over-year to $3.2 billion; the TTM value through Mar 2026 reached $3.2 billion, up 24.92%, while the annual FY2025 figure was $2.9 billion, 14.63% up from the prior year.
  • Other Non-Current Assets for Q1 2026 was $3.2 billion at Gsk, up from $2.9 billion in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $3.2 billion in Q1 2026 and troughed at $32.2 million in Q1 2022.
  • A 5-year average of $2.1 billion and a median of $2.2 billion in 2024 define the central range for Other Non-Current Assets.
  • Biggest five-year swings in Other Non-Current Assets: crashed 97.64% in 2022 and later surged 5546.5% in 2023.
  • Year by year, Other Non-Current Assets stood at $1.4 billion in 2022, then soared by 40.38% to $2.0 billion in 2023, then rose by 26.78% to $2.5 billion in 2024, then grew by 14.63% to $2.9 billion in 2025, then increased by 11.4% to $3.2 billion in 2026.
  • Business Quant data shows Other Non-Current Assets for GSK at $3.2 billion in Q1 2026, $2.9 billion in Q4 2025, and $2.9 billion in Q3 2025.